Rowan E Miller
Overview
Explore the profile of Rowan E Miller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kristeleit R, Devlin M, Clamp A, Gourley C, Roux R, Hall M, et al.
JAMA Oncol
. 2025 Feb;
PMID: 39913118
Importance: Advanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1)...
2.
El-Shakankery K, Kefas J, Palmer K, Houston A, Mukherjee U, Gao K, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518031
Background: Ethnic and socioeconomic disparities in cancer outcomes are exacerbated by clinical trial underrepresentation. This study aims to identify inequalities in ethnicity and socioeconomic features among ovarian cancer clinical trial...
3.
Steventon L, Man K, Nicum S, Miller R, Peleg Hasson S, Shah S, et al.
Oncologist
. 2024 Sep;
29(11):e1532-e1539.
PMID: 39245440
Introduction: Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated...
4.
Steventon L, Kipps E, Man K, Roylance R, Forster M, Wong I, et al.
Eur J Cancer
. 2024 Aug;
210:114301.
PMID: 39216173
Background: Inter-cycle delays to chemotherapy are often required to manage drug toxicity. The impact of delays on mortality is poorly characterised. This retrospective cohort study examined the association of treatment...
5.
Manchanda R, Sun L, Sobocan M, Rodriguez I, Wei X, Kalra A, et al.
J Natl Compr Canc Netw
. 2024 Jun;
22(2 D).
PMID: 38866043
Background: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and...
6.
Nuttall Musson E, Miller R, Mansour M, Lockley M, Ledermann J, Payne E
Leukemia
. 2023 Nov;
38(1):215-218.
PMID: 37978317
No abstract available.
7.
Wood G, Bunting C, Veli M, Arora R, Berney D, Alifrangis C, et al.
Front Oncol
. 2023 Nov;
13:1271647.
PMID: 37954076
Malignant germ cell tumours are a group of rare cancers whose incidence peaks in late adolescence and early adulthood. Dysgerminomas of the ovary and seminomas of the testis are analogous...
8.
Davis L, Miller R, Wong Y
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835509
Ovarian cancers are typically poorly immunogenic and have demonstrated disappointing responses to immune checkpoint inhibitor (ICI) therapy. Adoptive cellular therapy (ACT) offers an alternative method of harnessing the immune system...
9.
Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Fierheller C, Kalra A, et al.
BJOG
. 2023 Sep;
131(6):848-857.
PMID: 37752678
Objective: To evaluate patient preference for short (gist) or detailed/extensive decision aids (DA) for genetic testing at ovarian cancer (OC) diagnosis. Design: Cohort study set within recruitment to the Systematic...
10.
Hockings H, Miller R
Ther Adv Med Oncol
. 2023 May;
15:17588359231173183.
PMID: 37215065
The use of PARP inhibitors (PARPi) has transformed the care of advanced high-grade serous/endometrioid ovarian cancer. PARPi are now available to patients in both the first-line and recurrent platinum-sensitive disease...